International Stem Cell CORP ISCO revenue by segment, product and geography
In its fiscal year ending 2025-12-31, International Stem Cell CORP reported revenue across 3 business segments; the largest, Biomedical Market, was $8.5M (+2.6% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Biomedical Market$8.5Mshare n/a+2.6% yoy
- Anti Aging Market$598Kshare n/a-24.8% yoy
- Anti Aging Skincare Market$598Kshare n/a-24.8% yoy
member sum exceeds the consolidated figure: this axis carries more than one breakdown, so shares are not computed.
- Biomedical Market$2.78M-1040.1%-7.1% yoy
- Therapeutic Market-$2.53M949.1%+3.2% yoy
- Anti Aging Market-$510K191.0%-15.3% yoy
Members sum to the consolidated -$267K for this period.
- United States$7.84M86.1%+1.4% yoy
- Asia$719K7.9%-19.2% yoy
- Europe$448K4.9%+10.1% yoy
- Other Regions$95K1.0%+55.7% yoy
Members sum to the consolidated $9.1M for this period.
- Biomedical Market$2.17Mshare n/a+8.8% yoy
- Anti Aging Skincare Market$145Kshare n/a+8.2% yoy
- Anti Aging Market$145Kshare n/a+8.2% yoy
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.